Polycystic Kidney Disease News and Research RSS Feed - Polycystic Kidney Disease News and Research

Brandeis University researchers capture highest resolution images of cilia ever

Brandeis University researchers capture highest resolution images of cilia ever

Cilia, the cell's tails and antennas, are among the most important biological structures. They line our windpipe and sweep away all the junk we inhale; they help us see, smell and reproduce. When a mutation disrupts the function or structure of cilia, the effects on the human body are devastating and sometimes lethal. [More]
NIH study finds limited kidney benefit from more rigorous blood pressure treatment

NIH study finds limited kidney benefit from more rigorous blood pressure treatment

Using two drugs was no more effective than a single drug in slowing disease progression in people with autosomal dominant polycystic kidney disease (ADPKD), according to two studies funded by the National Institutes of Health. One of the studies also showed that rigorous blood pressure treatment slowed growth of kidney cysts, a marker of ADPKD, but had little effect on kidney function compared to standard blood pressure treatment. [More]
Otsuka Pharmaceutical begins tolvaptan Phase 3b study in patients with ADPKD

Otsuka Pharmaceutical begins tolvaptan Phase 3b study in patients with ADPKD

Otsuka Pharmaceutical Development & Commercialization, Inc., announced today that patient enrollment has begun for a new Phase 3b study of tolvaptan for adult patients with autosomal dominant polycystic kidney disease (ADPKD), the most common, life-threatening, inherited genetic kidney disorder. [More]
Study: Pravastatin slows down growth of kidney cysts in children, young adults with ADPKD

Study: Pravastatin slows down growth of kidney cysts in children, young adults with ADPKD

Results from a study by University of Colorado School of Medicine researchers show that pravastatin, a medicine widely used for treatment of high cholesterol, also slows down the growth of kidney cysts in children and young adults with autosomal dominant polycystic kidney disease (ADPKD). [More]
3 pioneering cell biologists win 2014 E.B. Wilson Medal from American Society for Cell Biology

3 pioneering cell biologists win 2014 E.B. Wilson Medal from American Society for Cell Biology

If cells were cars, then the three pioneering cell biologists just named winners of the 2014 E.B. Wilson Medal, the highest scientific honor of the American Society for Cell Biology, helped write the essential parts list. [More]
Otsuka obtains regulatory approval in Japan for pharmacological treatment of ADPKD

Otsuka obtains regulatory approval in Japan for pharmacological treatment of ADPKD

Otsuka Pharmaceutical Co., Ltd. today announced it has become the first company in the world to obtain regulatory approval for a pharmacological treatment of autosomal dominant polycystic kidney disease (ADPKD). Samsca (generic name: tolvaptan) has been approved in Japan in 7.5-mg and 15-mg tablet forms for extended use for the additional indication of ADPKD. Also, the new dosage form of 30-mg Samsca tablets has received approval for the indication of ADPKD. [More]
Scientists discover that natural product in grapefruit can prevent kidney cysts

Scientists discover that natural product in grapefruit can prevent kidney cysts

Scientists at Royal Holloway, University of London, have discovered that a natural product found in grapefruit can prevent kidney cysts from forming. [More]
Researchers discover protein required for growth of hair-like structures on cell surfaces

Researchers discover protein required for growth of hair-like structures on cell surfaces

A team of researchers from Penn State University and the University of California has discovered a protein that is required for the growth of tiny, but critical, hair-like structures called cilia on cell surfaces. [More]
EMA accepts Otsuka's marketing authorisation application for tolvaptan for treatment of ADPKD

EMA accepts Otsuka's marketing authorisation application for tolvaptan for treatment of ADPKD

Otsuka Pharmaceutical Co., Ltd. announced today that the European Medicines Agency (EMA) has accepted the submission of a marketing authorisation application (MAA) for the potential approval of tolvaptan for the treatment of autosomal dominant polycystic kidney disease (ADPKD). [More]
Holiday reads: Squabbling families, the psychology of Santa, holiday stress and chocolate chip cookies

Holiday reads: Squabbling families, the psychology of Santa, holiday stress and chocolate chip cookies

[T]his time of year the Internet is ripe with lists on how to avoid or mitigate family conflicts. At big gatherings, familiarity may not always breed contempt, but it sure can breed festering emotional wounds. Leonard Felder, a Los Angeles psychologist, has found that about three-quarters of us have at least one family member who annoys us. But why is it that the same minor jabs and annoying tics that are harmless coming from friends prompt epic screaming matches when uttered by relatives? ... Here are four theories as to why our families drive us nuts, and it would be nice of you to pay attention for once in your life (Olga Khazan, 12/23). [More]
Scientists at Salk Institute develop novel platform to study kidney diseases

Scientists at Salk Institute develop novel platform to study kidney diseases

​Diseases affecting the kidneys represent a major and unsolved health issue worldwide. The kidneys rarely recover function once they are damaged by disease, highlighting the urgent need for better knowledge of kidney development and physiology. [More]
Researchers generate three-dimensional kidney structures from human stem cells

Researchers generate three-dimensional kidney structures from human stem cells

Diseases affecting the kidneys represent a major and unsolved health issue worldwide. The kidneys rarely recover function once they are damaged by disease, highlighting the urgent need for better knowledge of kidney development and physiology. [More]
3Sbio acquires patents for DJ5 to delay hereditary renal disease in ADPKD patients

3Sbio acquires patents for DJ5 to delay hereditary renal disease in ADPKD patients

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, announced the acquisition of patents for DJ5, a novel non-TZD PPARgamma agonist with potential to retard progressive renal failure in patients with autosomal dominant polycystic kidney disease ("ADPKD'). [More]
Component of grape, citrus fruits block formation of kidney cysts

Component of grape, citrus fruits block formation of kidney cysts

A new study published today in British Journal of Pharmacology has identified that a component of grapefruit and other citrus fruits, naringenin, successfully blocks the formation of kidney cysts. [More]
Research uncovers defective process in patients with autosomal dominant polycystic kidney disease

Research uncovers defective process in patients with autosomal dominant polycystic kidney disease

New research has uncovered a process that is defective in patients with autosomal dominant polycystic kidney disease, a common cause of kidney failure. The findings, which appear in an upcoming issue of the Journal of the American Society of Nephrology (JASN), point to a new potential strategy for preventing and treating the disease. [More]
Discovery sheds new light on causes of debilitating diseases and birth defects

Discovery sheds new light on causes of debilitating diseases and birth defects

Danish researchers have just published findings that explain a previously unknown mechanism used by cells to communicate with one another. The research significantly contributes to understanding why some children are born with malformations and why children and adults may develop life-threatening diseases. [More]
New clinical algorithm to treat complex pediatric patients with ARPKD

New clinical algorithm to treat complex pediatric patients with ARPKD

A collaborative team of physician-scientists at the Medical College of Wisconsin and Children's Hospital of Wisconsin Research Institute has developed a new evidence-based, clinical algorithm to help physicians treat complex patients with autosomal recessive polycystic kidney disease. [More]
FDA accepts Otsuka Pharmaceutical's tolvaptan NDA for priority review

FDA accepts Otsuka Pharmaceutical's tolvaptan NDA for priority review

Otsuka Pharmaceutical Co., Ltd. announced today that the U.S. Food and Drug Administration has accepted for priority review the company's new drug application for the potential use of tolvaptan for the treatment of autosomal dominant polycystic kidney disease. [More]
Rensselaer professor awarded NIH grant to explore cellular function with links to diverse diseases

Rensselaer professor awarded NIH grant to explore cellular function with links to diverse diseases

The interior of every cell within our bodies is crisscrossed with a network of molecular highways upon which nutrients, replacement parts, and other vital materials travel to their appropriate location. [More]
Researchers to develop new diagnostic tools and treatments for people with rare diseases

Researchers to develop new diagnostic tools and treatments for people with rare diseases

A multi-million Euro initiative is bringing together researchers from across the world to develop new diagnostic tools and new treatments for people with rare diseases and to connect research data in this area on a global scale. [More]